Allman to headline Merck's Tune In to Hep C awareness effort

Share this article:
Merck is launching a chronic hepatitis C awareness campaign featuring rocker and hepatitis C sufferer Gregg Allman, whose Allman Brothers Band will headline a benefit concert on World Hepatitis Day on July 27, in New York.

Allman underwent a liver transplant a year ago because of chronic hepatitis C and said in a statement: “I want to tell [sufferers], don't wait. Doing nothing is not an option. They need to talk with their doctor.”

Three million Americans have the disease, which can damage the liver over time and lead to cirrhosis, end-stage liver disease and liver cancer. As many as four-fifths of those infected don't know they have the virus, said Merck.

The campaign, dubbed Tune In to Hep C, is being co-sponsored by the American Liver Foundation, whose acting CEO Newton Guerin said: “Gregg's willingness to share his story will open the door for meaningful dialogue that can help reduce stigma and the lack of understanding surrounding chronic hepatitis C. 

Merck's Victrelis, the first in a new class of hepatitis C drugs, won FDA approval in May, followed weeks later by rival Incivek, from Vertex.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...